Stories

Leukemias with ALK mutations identified, may respond to ALK inhibitors

Leukemias with ALK mutations identified, may respond to ALK inhibitors

June 01, 2015
Mutations in the ALK gene were identified in the tumors of two leukemia patients, and laboratory studies indicated that leukemias harboring these mutations may respond to ALK inhibitors such as crizotinib and ceritinib, according to a study published in Cancer Research that was conducted by researchers with the Knight Cancer Institute at Oregon Health & Science University.

OHSU invites community members to join the War on Skin Cancer

May 28, 2015
Research Expo & Sun Safety Event to educate, detect and advance skin cancer prevention and treatment PORTLAND, Ore. – Just in time for summer, the OHSU Knight Cancer Institute and the OHSU Department of Dermatology will host a Skin Cancer Research ...
See more stories